Multivalent Albumin Binders Extend Therapeutic Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic peptides and proteins have short half-lives in vivo, limiting their efficacy and requiring frequent dosing, which can lead to dose-fluctuation-related complications and reduced patient compliance.
Innovation Solution
Development of albumin binding polypeptides that comprise at least one immunoglobulin single variable domain (ISVD) specifically binding to human serum albumin (HSA) and an additional moiety binding to HSA, which significantly extends the in vivo serum half-life of therapeutic compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If therapeutic peptides and proteins are administered, then therapeutic effect is achieved, but serum half-life is short requiring frequent dosing
Solution Approach 1:
The patent combines multiple albumin-binding moieties (ISVDs and other binding domains) into a single polypeptide structure. This merging of multiple binding functions creates a multivalent albumin binder that achieves prolonged serum half-life through enhanced binding capacity to albumin, thereby reducing dosing frequency while maintaining therapeutic effect.
Solution Approach 2:
The invention creates composite polypeptide structures that integrate different types of albumin-binding domains (immunoglobulin single variable domains and other binding moieties) into a unified molecule. This composite approach leverages the complementary binding properties of different domains to achieve superior and prolonged albumin interaction, extending serum half-life beyond what single-domain binders can achieve.
2Duration of action of moving object
If multiple binding moieties are added to extend half-life, then serum half-life is increased, but polypeptide complexity increases
Solution Approach 1:
The patent employs modular segmentation by using standardized albumin-binding domains (such as ISVDs with defined CDR regions) that can be independently designed and then assembled into multivalent polypeptides. This segmentation allows systematic construction of complex binders from interchangeable functional units, making the design and production of high-valency albumin binders more manageable despite their complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The albumin binding polypeptides achieve a substantially increased in vivo serum half-life, allowing for lower doses and less frequent administration of therapeutic compounds, thereby reducing adverse events and improving compliance.
Implementation Method 1
at least one immunoglobulin single variable domain (ISVD) which specifically binds to a serum albumin protein or at least one human serum albumin protein
Implementation Method 2
at least one further moiety specifically binding to a serum albumin protein or at least one human serum albumin protein
Data Source
AI summary
The present technology relates to bi- and multivalent albumin binders. In particular, the present technology relates to novel and improved human serum albumin binders, specifically to polypeptides that comprise (i) at least one immunoglobulin single variable domain (ISVD) which specifically binds to a serum albumin protein or at least one human serum albumin protein and (ii) at least one further moiety specifically binding to a serum albumin protein or at least one human serum albumin protein.